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Adjuvant Chemotherapy for Resected Non-small Cell
Lung Cancer
Christopher M. Booth, MD, FRCPC, and Frances A. Shepherd, MD, FRCPC
Abstract: Despite improved surgical techniques, relapse and mor-
tality rates remain high among patients with resected non-small cell
lung cancer. Numerous randomized controlled trials in the 1980s
and 1990s were unable to demonstrate a consistent survival benefit
for adjuvant chemotherapy. However, in the past 2 years, the results
of three pivotal trials have unequivocally shown the benefit to
adjuvant treatment in resected non-small cell lung cancer. In this
review, we describe early adjuvant trials and highlight the recent
landmark studies in this disease. The focus of ongoing and future
research efforts is also discussed.
(J Thorac Oncol. 2006;1: 180–187)
Lung cancer is the leading cause of cancer mortality in thewestern world and accounts for more deaths than breast,
colon, and prostate cancers combined.1 Surgical resection
remains the treatment of choice for early-stage non-small cell
lung cancer (NSCLC), yet 5-year survival rates for stage I
and II disease are only 60 to 70% and 35 to 40%, respective-
ly.2 Recurrences tend to occur at extrathoracic sites, suggest-
ing the presence of micrometastatic disease at the time of
surgery. These observations led to the hypothesis that adju-
vant systemic therapy should improve outcomes in resected
NSCLC. However, it has taken almost 3 decades of clinical
research to prove this hypothesis correct.
Early efforts to improve the outcome of resected
NSCLC involved the use of postoperative radiotherapy.
However, a meta-analysis published in 1998 involving nine
randomized controlled trials (RCTs) suggested a detrimental
effect of postoperative radiotherapy in NSCLC. Radiotherapy
was associated with a 21% relative increase in risk of death,
which translated to an absolute decrease of 7% in 2-year
overall survival (reducing survival from 55% to 48%).3
Platinum-based chemotherapy regimens, the standard of
care for the first-line treatment of advanced NSCLC, have been
tested against observation in the adjuvant setting in North Amer-
ica and Europe since the 1970s. Investigators in Japan, however,
have largely studied milder oral regimens involving tegafur (an
oral 5-fluorouracil derivative) plus uracil (UFT). Despite numer-
ous trials, until 2004, most authorities felt there was insufficient
evidence to recommend the use of adjuvant chemotherapy for
resected NSCLC. However in the last 2 years, the results of three
pivotal clinical trials have led to a major change in practice
patterns, with most oncologists now strongly recommending
adjuvant systemic therapy in good performance status patients
with resected NSCLC.4–6
In this review, we describe early RCTs of adjuvant
chemotherapy for completely resected NSCLC (limited to
trials with 100 patients) of both platinum-based and oral
adjuvant chemotherapy. Emphasis is on the recently com-
pleted landmark studies. The focus of ongoing and future
research efforts in this field is also discussed.
PLATINUM-BASED CHEMOTHERAPY
Studies Conducted before 1990
Several clinical trials in the 1970s and 1980s evaluated
the role of adjuvant cyclophosphamide, doxorubicin, and
cisplatin (CAP) chemotherapy in resected NSCLC (Table 1).
Results from two of these trials suggested a possible benefit
from adjuvant chemotherapy, but the differences were not
statistically significant.7,8 The Lung Cancer Study Group trial
772 randomized 141 patients with completely resected stage
II and III NSCLC to receive six cycles of CAP chemotherapy
or bacillus Calmette-Guerin and levamisole immunotherapy.7
Both median survival (23 versus 16 months) and overall
survival at 2 years (41% versus 30%) showed non-significant
trends in favor of CAP chemotherapy. In the subsequent
LCSG 801 trial, Feld et al.9 randomized 283 patients with
stage IB and II NSCLC to four cycles of CAP chemotherapy
or observation. Among the 269 eligible patients, no statisti-
cally significant survival difference was observed after a
mean follow-up of 3.8 years.
A Finnish trial of adjuvant CAP chemotherapy that was
limited to patients without nodal involvement by tumor (T1-
3N0) was the second study to suggest that adjuvant chemo-
therapy conferred a survival advantage in resected NSCLC.
Despite the small size of this trial (only 110 patients), a
survival advantage of borderline significance was seen in
favor of chemotherapy (P  0.05). Patients with T2 tumors
seemed to derive the greatest benefit from chemotherapy,
although the confidence of this observation is limited by the
small number of patients in the subset.8 However, given the
lack of a convincing survival benefit from CAP in any of
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these adjuvant trials, its use was largely restricted to the
research setting.
REGIMENS CONTAINING SECOND-
GENERATION VINCA ALKALOIDS AND
EPIPODOPHYLLOTOXINS
In the 1990s, emphasis shifted from alkylating agents to
the use of platinum-based regimens using the vinca alkaloids
vinblastine and vindesine (Table 1). Two small trials evaluating
the combination of vindesine/cisplatin failed to show a survival
benefit versus postoperative observation alone.10,11 The large
multicenter Adjuvant Lung Project Italy (ALPI) trial random-
ized 1196 patients to receive three cycles of adjuvant mitomycin,
vindesine, and cisplatin chemotherapy or observation alone.12
Radiotherapy was permitted according to each center’s existing
treatment policy, and its use was equal in both treatment groups
(43%). After a median follow-up of 64.5 months, no statistically
significant differences in overall or progression-free survival
were detected between treatment groups, nor was survival by
treatment group affected by disease stage.
TABLE 1. Randomized Trials of Platinum-Based Adjuvant Chemotherapy
Reference Stage Treatment Patients (n) Median survival Survival (yr) 1 2 3 P value
Douillard et al,
2005 (6)
Completely resected
Stage I-III
Vinor/P 407 65.8 mo 83.5% 67.9% 51.2% 0.013
Observation 433 43.8 mo 80.4% 62.8% 42.6% (HR 0.79)
Park et al,
2005 (13)
Completely resected
Stage I
MVP 59 11.9 yr – – 81.4% (5 yr) 0.19
Observation 59 Not reached – – 74.6% (5yr)
Waller et al,
2004 (14)
Completely and
incompletely resected
Stage I-III
Multiple Cisplatin-based 192 – – – – 0.90
Observation 189 – – – – (HR 1.02)
Tada et al,
2004 (11)
Completely resected
Stage III (N2)
VdsP 59 36 mo – – 28% (5 yr) 0.89
Observation 60 36 mo – – 36% (5 yr)
Winton et al,
2004 (5)
Completely resected
Stage IB and II
Vinor/P 243 94 mo – – 69% (5 yr) 0.012
Observation 239 73 mo – – 54% (5 yr) (HR 0.70)
Strauss et al
2004 (4)b
Completely resected
Stage IB
Carbo/Pacl 173 – 95% 93% 71% (4 yr) 0.028
Observation 171 – 94% 84% 59% (4 yr) (HR 0.62)
Arriagada et al,
2003 (15)
Completely resected
Stage I-III
Multiple Cisplatin-based 932 51 mo – – 44% (5 yr) 0.03
Observation 935 44 mo – – 40% (5 yr) (HR 0.86)
Scagliotti et al,
2003 (12)
Completely resected
Stage I-III
MVP 606 55 mo – – 48% (5 yr) 0.59
Observation 603 48 mo – – 42% (5 yr) (HR 0.96)
Keller et al,
2000 (18)
Completely resected
Stage II-III
EP-RT 246 38 mo – – 33% (5 yr) 0.56
RT 242 39 mo – – 39% (5 yr)
Dautzenberg et
al, 1995 (17)
Completely resected
Stage I-III
COPAC/ RT 138 1.3/1.2 yra – 38/36%a 17/19%b 0.68
RT 129 2.1/0.8 yra – 54/22%a 34/6%b 0.03/0.003a
Ohta et al,
1993 (10)
Completely resected
Stage III
VdsP 90 31 mo – – 35% (5 yr) 0.86
Observation 91 37 mo – – 41% (5 yr)
Feld et al,
1993 (9)
Completely resected
T2N0, T1N1
CAP 136 73 mo 89% – 54% (5 yr)b 0.92
Observation 133 76 mo 88% – 50% (5 yr)b
Niiranen et al,
1992 (8)
Completely resected
T1-3N0
CAP 54 7 yr – – 67% (5 yr) 0.05
Observation 56 5 yr – – 56% (5 yr)
Lad et al,
1988 (16)
Incompletely resected
Stage I-III
CAP-RT 78 20 mo 68% 41% 25%b NS
RT 86 13 mo 54% 32% 25%b
Holmes et al,
1986 (7)
Completely resected
Stage II-III
CAP 62 23 mo 75% 41% – 0.078
BCG 68 16 mo 64% 30% –
CAP, cyclophosphamide, doxorubicin, cisplatin; BCG, bacillus Calmette et Guerin; RT, radiotherapy; VdsP, vindesine, cisplatin; EP, etoposide and cisplatin; COPAC,
cyclophosphamide, doxorubicin, cisplatin, vincristine, lomustine; MVP, mitomycin C, vindesine, cisplatin; HR, hazard ratio; Carbo/Pacl, carboplatin, paclitaxel; Vinor/P, vinorelbine,
cisplatin.
aN0-N1/N2
bUnpublished Lung Cancer Study Group data.
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A recently published study by Park et al.13 also failed to
find a significant survival benefit for postoperative mitomycin
C, vinblastine, and cisplatin. This randomized study of 118
patients with completely resected stage I NSCLC (82% stage
IB) had a mean follow-up of 7.3 years. Although there was a
significant improvement in disease-free survival for the che-
motherapy group, the 5- and 10-year overall survival rates of
74.6% and 56.3% in the control group and 81.4% and 65.0%
in the chemotherapy group, respectively, were not signifi-
cantly different (P 0.19). The lack of statistical significance
may be the result of the relatively small sample size.
The Big Lung Trial differs from the other trials in-
cluded in this summary in that it included some patients who
had received preoperative induction chemotherapy (3%) and
some who had undergone incomplete resections (6 to 15%).14
The 381-patient trial used mainly second-generation chemo-
therapy agents and, like the ALPI trial, failed to detect a
statistically significant survival benefit for preoperative or
postoperative chemotherapy.
The International Adjuvant Lung Cancer Trial (IALT)
is the largest RCT of adjuvant chemotherapy reported to date
and was the first major trial to show a significant benefit to
adjuvant chemotherapy in resected NSCLC.15 To facilitate
accrual, the following parameters were allowed to vary by
center: disease stage, cisplatin dose, second chemotherapy
agent (etoposide, vinorelbine, vinblastine, or vindesine), and
use of radiotherapy after chemotherapy. After a median
follow-up of 56 months, overall survival for the 1867 ran-
domized patients was superior in the chemotherapy treatment
arm, with a 4.1% absolute survival benefit at 5 years and a
14% relative reduction in the risk of death (hazard ratio [HR]
0.86; 95% CI, 0.76–0.98; P  0.03). The survival advantage
observed with chemotherapy was maintained regardless of
radiation (administered in 30% of study patients), choice
of second drug (50% of patients received etoposide), dose of
cisplatin, or disease stage. The third-generation vinca alkaloid
combination vinorelbine/cisplatin regimen was used in only
26.8% of study patients.
ADJUVANT CHEMOTHERAPY AND
RADIOTHERAPY
Three studies failed to show benefit from postoperative
chemotherapy and radiotherapy compared with postoperative
radiotherapy alone. The Lung Cancer Study Group 791 en-
rolled patients with incompletely resected NSCLC defined as
either a positive resection margin or microscopic involvement
by tumor in the highest lymph node sampled.16 Patients
received postoperative radiation followed by six cycles of
CAP chemotherapy or observation alone. There was no
difference in overall survival between the two groups.
In a French Cooperative Group trial, patients with
completely resected stage I-III NSCLC were randomized to
receive radiation alone or radiation followed by vincristine,
lomustine, and CAP (COPAC) chemotherapy. The addition
of chemotherapy did not result in any benefit compared with
radiation alone.17
Finally, in the most recent study, the Eastern Cooper-
ative Oncology Group (ECOG) randomized 488 patients to
postoperative adjuvant radiotherapy or the same radiotherapy
administered concurrently with four cycles of etoposide-
cisplatin.18 After a median follow-up of 44 months, survival
was comparable for both treatment groups.
META-ANALYSES
The first definitive meta-analysis examining the effi-
cacy of chemotherapy in NSCLC was published in 1995.19
The analysis that compared curative surgery with or without
chemotherapy included 14 trials (eight used cisplatin-based
therapy) involving 4357 patients. This review included indi-
vidual patient data and was conducted on an intent-to-treat
basis. Across the five trials involving alkylating agents (n 
2145), postoperative chemotherapy resulted in a statistically
significant survival disadvantage. Compared with surgery
alone, chemotherapy was associated with an absolute de-
crease in survival of 5% at 5 years and an overall relative
increase in risk of death (HR 1.15; 95% CI, 1.04–1.27; P 
0.005).
However, for the eight trials involving adjuvant cispla-
tin-based regimens (n  1394 patients), chemotherapy was
associated with a trend toward improved survival, with an
absolute benefit of 5% at 5 years that corresponded to a 13%
relative reduction in risk of death (HR 0.87; 95% CI, 0.74–
1.02; P  0.08).
In the analysis of surgery and radiotherapy with or
without chemotherapy, there were seven trials (n  807
patients); six involved cisplatin-based chemotherapy. Che-
motherapy was not associated with a significant survival
benefit when all trials were included (HR 0.98; P  0.76) or
for the six cisplatin-based trials (HR 0.94; 95% CI, 0.79–
1.11; P  0.46).
Several subsequent review articles and meta-analyses
have also confirmed the value of adjuvant cisplatin-based and
UFT-based chemotherapy for NSCLC.19–25 These analyses
have reported HRs ranging from 0.74 at 7 years for adjuvant
UFT22 to 0.89 overall for cisplatin-based chemotherapy24,25
with absolute improvements in survival at 5 years of approx-
imately 5%.
In summary, although most of the early chemotherapy
trials did not show a significant survival benefit in resected
NSCLC, a signal of potential benefit emerged even in some
of the trials performed in the CAP era. It is clear now that the
small trials performed in the 1970s and 1980s were severely
underpowered, with none of them having a sample size that
would be adequate to confirm a modest but potentially clin-
ically meaningful survival benefit. This was true even for the
first meta-analysis that demonstrated a 5% absolute survival
benefit at 5 years, yet the difference was not significant.3 In
contrast, in the IALT trial that had almost 2000 patients, there
was a significant difference in overall survival (HR 0.86;
P  0.03) and a 4.1% absolute improvement in 5-year
survival. However, the use of adjuvant chemotherapy was not
widely adopted despite the significant results of IALT. This
may be attributed to the negative results of the ALPI, Big
Lung Trial, and ECOG studies12,14,18 and because many
oncologists and patients thought that the degree of treatment-
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related toxicity outweighed the potential 5% gain in overall
survival.
MODERN CHEMOTHERAPY REGIMENS
The results of two North American Cooperative Group
trials4,5 were presented at the 2004 annual meeting of the
American Society of Clinical Oncology. The dramatic results
from these studies led to the widespread adoption of adjuvant
chemotherapy for resected NSCLC. These studies, together
with the recently presented European Cooperative trial,6 are
reviewed in detail in this section. Important study character-
istics are presented in Table 2.
The Cancer and Leukemia Group B trial (CALGB
9633)4 randomized patients with resected stage IB (T2N0M0)
tumors to four cycles of adjuvant paclitaxel (200 mg/m2) and
carboplatin (AUC 6 mg/mL x min) over 12 weeks versus
observation alone. The study was stopped prematurely by the
data and safety monitoring board after enrolling 344 of a
planned 384 patients. The treatment was well tolerated with
no chemotherapy-related toxic deaths, and the most common
grade 3/4 toxicity was neutropenia (36%). Compliance with
all four cycles of treatment was also good; 85% of random-
ized patients received four cycles of chemotherapy. Despite
the relatively short median follow-up of only 34 months, a
statistically significant survival advantage was detected for
adjuvant chemotherapy with an absolute benefit of 12% at 4
years (71% versus 59%; P  0.028). A multivariate analysis
adjusting for important prognostic variables (including age,
gender, tumor size, and presence of symptoms) confirmed a
significant reduction in the risk of death from lung cancer
with adjuvant chemotherapy (Cox model: HR 0.62; 95% CI,
0.40–0.97; P  0.034). Lung cancer-specific mortality was
also significantly reduced with the use of chemotherapy (HR
0.51; 95% CI, 0.29–0.89; P  0.018).
The results of the National Cancer Institute of Canada
Clinical Trials Group (NCIC-CTG) North American inter-
group study JBR.10 were also presented at the ASCO 2004
meeting and published in full in 2005.5 In this study, 482
patients with completely resected stages IB and II (excluding
T3N0) tumors were randomized to receive four cycles of
adjuvant vinorelbine (25 mg/m2 weekly) and cisplatin (50
mg/m2 days 1 and 8) over 16 weeks or observation alone.
Postoperative radiotherapy was not permitted in either
CALGB 9633 or JBR.10.
The JBR.10 study regimen was associated with signif-
icantly more hematological toxicity than CALGB 9633, and
there were two treatment-related deaths. Grade 3/4 neutrope-
nia was seen in 73% of patients, and only 45% of randomized
patients completed four cycles of therapy. The incidence of
febrile neutropenia was 7% in the treatment arm. However,
other than fatigue (15%), grade 3/4 toxicity rates were un-
common (10%). Despite these toxicities, patients who re-
ceived adjuvant chemotherapy reported only modest impair-
ment of their quality of life while on treatment, and quality of
life improved within the first year after surgery.26
After a median follow-up of 5.1 years, overall survival
strongly favored the adjuvant chemotherapy arm with an
absolute survival benefit of 15% at 5 years (69% versus 54%)
and a 30% relative reduction in the risk of death (P 0.012).
Subgroup analysis demonstrated no statistically significant
benefit from adjuvant chemotherapy in the patients with stage
IB disease (survival benefit at 5 years 7%; P  not signifi-
cant). However, because of smaller numbers (45% of study
participants), lower than expected events rates in this sub-
TABLE 2. Recent Clinical Trials Comparing Adjuvant Chemotherapy Versus Observation for Patients with Resected NSCLC
CALBG-96334 JBR.105 ANITA-16
N 344 482 840
Stage IB IB (45%), II (55%) IB (35%), II (30%), IIIA (35%)
Median age (yr) 61 61 59
Median follow-up (mo) 34 61 70
ECOG performance status 0-1 0-1 0-2
Treatment regimen Paclitaxel 200 mg/m2 Carboplatin
AUC 6 mg/mL  min
Vinorelbine 25 mg/m2 weekly  16 Vinorelbine 30 mg/m2 weekly 16
Every 3 weeks for four cycles Cisplatin 50 mg/m2 days 1 and 8 Cisplatin 100 mg/m2 day 1
Every 4 weeks for four cycles Every 4 weeks for four cycles 25% received
radiotherapy
Compliance 85% received four cycles, 55%
received four cycles at full dose
45% completed four cycles 56.3% received full planned dose of vinorelbine
76.1% received full planned dose of cisplatin
Grade 3/4 neutropenia 36% 73% 85%
Outcomes 4-year survival 5-year survival 5-year survival:
(HR, 95% CI) 71% vs. 59% 69% vs. 54% 51% vs. 43%
HR 0.62 (0.41-0.95); P  0.028 HR 0.69 (0.52-0.91); P  0.009 HR 0.79 (0.66-0.95)
Comment Very well tolerated regimen No survival benefit in stage IB
patients
No survival benefit in stage IB patients
ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; AUC, area under the curve; CALGB, Cancer and Leukemia Group B; ANITA, Adjuvant Navelbine International
Trialists Association.
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group, and the lack of a statistically significant stage-by-
treatment interaction, the authors concluded that adjuvant
vinorelbine and cisplatin should become standard of care for
patients with both stage IB and II completely resected
NSCLC.
The most recent trial to be presented is the Adjuvant
Navelbine International Trialists Association (ANITA)
study.6 This cooperative European study randomized patients
with resected stages IB, II, and IIIA NSCLC to receive four
cycles of vinorelbine (30 mg/m2 weekly) and cisplatin (100
mg/m2 every 4 weeks) over 16 weeks or observation alone.
The use of radiotherapy was at the discretion of participating
centers. Unlike the previous two studies in which only pa-
tients with ECOG performance status 0-1 were eligible, this
study included patients with poorer performance status
(ECOG 0-2). The study groups were equal at baseline with
respect to important prognostic factors, and both study arms
showed approximately even proportions of the various stages
of disease. More patients in the observation arm received
postoperative radiotherapy compared with those in the che-
motherapy arm (approximately 30% versus 20%).
Toxicity in the ANITA trial was greater than that in
JBR.10. Grade 3/4 neutropenia was seen in 85% of patients,
and febrile neutropenia occurred in 12.5% of treated patients.
There were six toxic deaths in the treatment group. Rates of
grade 3/4 infection, anemia, nausea/vomiting, anorexia, and
asthenia were all10% in this trial. The median relative dose
intensity was 58.6% and 88.9% for vinorelbine and cisplatin,
respectively.
Despite the added toxicity, after a median follow-up of
70 months, overall survival (65.8 versus 43.8 months),
2-year survival (67.9% and 62.8%), and 5-year survival
(51.2% versus 42.6%) were significantly improved with ad-
juvant therapy. Subgroup analysis suggested that patients
with stage IB disease did not benefit significantly from
adjuvant chemotherapy. A further finding of subgroup anal-
ysis was that patients with resected stage IIIA disease derived
significant benefit from postoperative radiotherapy. The au-
thors concluded that adjuvant vinorelbine and cisplatin
should be considered the standard of care for patients with
resected stage II and IIIA NSCLC.
UFT-BASED CHEMOTHERAPY
Oral Agents Alone or in Combination with
Other Chemotherapy Agents
In Japan, the oral antimetabolite UFT either alone or
combined with other intravenous agents has been evaluated in
several studies (Table 3). In the largest fully published trial,
Kato et al.36 administered UFT postoperatively for 2 years to
patients with resected stage I NSCLC. The study included
976 patients and reported a statistically significant survival
benefit in favor of UFT administration (HR 0.71; 95% CI,
0.52–0.98). However, in a smaller RCT of patients with stage
I and II NSCLC, Endo et al.35 did not find a survival benefit
associated with adjuvant UFT monotherapy compared with
observation alone.
Other investigators have assessed the combination of
UFT with intravenous chemotherapy. Wada et al.31 per-
formed a three-armed study in which 310 patients with
resected stages I-III NSCLC were randomized to observation,
1 year of UFT alone, or three cycles of vindesine/cisplatin
followed by 1 year of UFT. Although survival was signifi-
cantly improved with UFT alone, the combination of UFT
with intravenous chemotherapy did not confer a statistically
significant survival benefit. However, a similar three-armed
study involving only 150 patients with stage I disease showed
conflicting results. Imaizumi et al.37 reported that the combi-
nation of vindesine/cisplatin (two cycles) and UFT (2 years)
was associated with significantly improved overall survival
compared with observation, whereas there was no significant
difference in outcome with UFT alone.
In a meta-analysis of UFT chemotherapy22 that pooled
individual patient data from six RCTs (n  2003 patients,
96% stage I disease), survival rates at 5 and 7 years were
significantly higher in the surgery plus UFT group (81.5%
and 76.5%) than in the surgery-alone group (77.2% and
69.5%, respectively; P 0.011 and P 0.001, respectively).
DISCUSSION AND CONCLUSION
Although meta-analyses and some early RCTs sug-
gested a potential benefit to adjuvant chemotherapy for re-
sected NSCLC in the 1990s, it was not until the publication
of three recent landmark studies that adjuvant chemotherapy
was fully established as the standard of care. Questions that
remain unanswered are: which patients should be treated, at
what stage of disease, and with which chemotherapy regi-
men?
Whereas the JBR.10 and ANITA trials (in preplanned
subset analyses) did not show a significant benefit for patients
with stage IB disease, the CALBG study, which enrolled only
patients with stage IB disease, showed a clear benefit.4–6
However, the follow-up of this trial is not yet mature, and the
survival curves as presented suggest that the absolute benefit
at 5 years will be less than 10%. At this time, thoracic
surgeons and medical oncologists should keep an open mind,
and individual treatment decisions should be reached after an
assessment of patient suitability for chemotherapy and after a
full discussion of the individual trial results with each patient.
The use of oral UFT has shown activity in Japanese studies,
particularly in those with stage I adenocarcinomas. However,
this regimen remains untested in the western world and,
because of potential pharmacogenomic differences, its clini-
cal use should be restricted to the patient population in which
it has been studied. The results of the JBR.10 and ANITA
studies clearly and unequivocally demonstrate that patients
with stage II and IIIA NSCLC benefit from adjuvant vinorel-
bine and cisplatin, and this or similar treatment should be
offered to fit patients able to tolerate therapy.
In the advanced disease setting, all platinum-based
doublet chemotherapy combinations incorporating vinorel-
bine, gemcitabine, and the taxanes paclitaxel and docetaxel
have demonstrated similar activity and efficacy.38 Therefore,
it is reasonable to conclude that these regimens should have
similar efficacy in the adjuvant setting. For that reason, some
oncologists have elected to use as adjuvant therapy the
regimen used most frequently in their centers for advanced
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TABLE 3. Trials Comparing Surgery with or without Chemotherapy Regimens Involving Oral Agents
Reference Patients (n) Treatment Stage
5-Year
survival (%) P value Comments
Imaizumi et al,
2005 (37)
50 PVds  UFT I 87.9 0.045 In multivariate analyses, postoperative
PVdsUFT was the only prognostic factor
for survival.
50 UFT 67.1 PVdsUFT vs.
surgery
50 Observation 66.3
Kato et al, 2004
(36)
491 UFT I 88 0.04 Includes only adenocarcinomas.
488 Observation 85 Subgroup analyses: 5-year survival benefit
with UFT: T2 (85% vs. 74%), T1 (89%
vs. 90%) P  0.04.
Endo et al, 2003
(35)
109 UFT I, and II 79 0.7013 Subgroup analyses: no treatment
differences by disease stage or tumor
histology.
110 Observation 75
Tada et al, 2002
(34)a
172 UFT IA and IB 74 (8-year) 0.045 Subgroup analyses: survival longer with
UFT for stage I adenocarcinoma (8-year,
76% vs. 60%, P  0.065).
Observation 58 (8-year)
95 PVds  UFT II-IIIA NR NS
Observation
Tanaka et al, 2001
(33)a
163 UFT IA and IB 86 For IA, 0.027 Subgroup analyses: survival longer with
UFT for stage IA adenocarcinoma
(P  0.011) but not for squamous cell
carcinoma.
169 Observation 77 For IB, NS
Wada et al, 1999
(32)
109 PVdsM UFT I and II 77 0.39 Subgroup analyses: 5-year survival benefit
with UFT for T1N0 patients (91% vs.
75%, P  0.03) but not for other disease
stages.
116 Observation 71
Wada et al, 1996
(31)
109 PVds  UFT I-III 61 0.053 UFT vs. observation, P  0.022.
103 UFT 64 PVdsUFT vs. observation, P  0.083.
98 Observation 49 Overall survival benefit with PVdsUFT
(HR 0.64; 95% CI, 0.42-0.97; P 
0.037) and UFT alone (HR 0.55; 95%
CI, 0.36-0.86; P  0.009) in regression
analysis adjusted for stage, tumor
histology, age, and sex.
SGACLC 1995
(30)
155 PA  UFT I-III 62 0.347 Survival benefit with PAUFT in
regression analysis adjusted for disease
stage, tumor histology, age, and sex
(overall P  0.044; disease-free P 
0.036).
154 Observation 58
Kunishima et al,
1992 (29)a
144 CM  Ftorafur I-III 56 0.147 Subgroup analyses: survival benefit with
chemotherapy for pN0 (5-year: overall
67% vs. 51%, P  0.025; disease-
free 71% vs. 56%, P  0.020).
138 Observation I-III 46
Sawamura et al,
1988 (27)a
Adenocarcinoma No statistically significant survival
differences between treatment groups for
subgroups of disease stage or histology.
106 Ftorafur I 55* 0.2992
MA Ftorafur II-III
100 Observation I-III 64
Kuwahara et al,
1992 (28)a
Squamous cell No statistically significant survival
differences between treatment groups for
subgroups of disease stage or histology.
101 Ftorafur I 57* 0.9401
Ftorafur/P II
Ftorafur/P/RT III
104 Observation I-II 62
RT III 62
MA, mitomycin, doxorubin; P, cisplatin; RT, radiotherapy; CM, cyclophosphamide, doxorubicin; PA, cisplatin, doxorubin; PVds, cisplatin, vindesine; UFT, uracil plus tegafur;
HR, hazard ratio; PVdsM, cisplatin, vindesine, mitomycin.
*Estimated from published survival curve.
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stage IV NSCLC. Although such a decision is clearly not
evidence-based, it does not seem unreasonable, and the fa-
miliarity and comfort level that staff develop with the fre-
quent usage of a small number of regimens may allow for
better patient support and education and, potentially, even to
lower rates of toxicity.
The dosing schedules used in both the JBR.10 and
ANITA trials were associated with substantial hematological
toxicity. Because of this toxicity and the low rate of drug
delivery in these trials, many clinicians have modified the
treatment schedules into a better tolerated 21-day cycle with
vinorelbine 25-30 mg/m2 on days 1 and 8 and cisplatin 75–80
mg/m2 on day 1. However, it is important to recognize that
this regimen is not the schedule used in either clinical trial
and that the impressive survival benefit in both JBR.10 and
ANITA was seen despite the relatively high rates of hema-
tological toxicity and low dose delivery. Furthermore, a
recent analysis of three trials of chemotherapy for advanced
NSCLC found the presence of neutropenia to be associated
with increased survival. This suggests that hematological
toxicity may be a biological marker of drug activity and its
absence may potentially reflect underdosing.39
The selection of patients appropriate for adjuvant ther-
apy depends largely on performance status and accompany-
ing co-morbid conditions. Whereas the CALGB and JBR.10
studies enrolled only patients with ECOG performance status
0-1, the ANITA trial also included patients with ECOG
performance status 2. It is also important to note that median
patient age in these studies was 59-61 years, whereas the
median age of all patients diagnosed with NSCLC is older
than 70 years. Treatment of the elderly patient with lung
cancer is a frequently debated topic. Most recent opinions
suggest that physiologic (not chronologic) age should dictate
which patients are most appropriate for therapy.40,41 In the
less robust elderly patient for whom platinum-based therapy
may not be appropriate, single-agent treatment has been
shown to prolong survival in the advanced setting.42 Whether
this may extend to the adjuvant setting would require pro-
spectively designed trials.
Despite the major therapeutic advances in adjuvant
chemotherapy for resected NSCLC achieved in the past few
years, a significant proportion of patients will ultimately
relapse and die from their disease. The addition of molecu-
larly targeted agents to chemotherapy in the adjuvant setting
seems to be a logical next step in view of their recently
demonstrated benefit in the advanced disease setting.43,44
Indeed, a North American intergroup trial that compared
adjuvant gefitinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, to placebo was initiated.
However, a recently presented study of maintenance gefitinib
versus observation alone after concurrent chemotherapy and
radiation for unresectable stage III NSCLC suggested a non-
significant survival disadvantage to the use of gefitinib.45
Therefore, the intergroup study of adjuvant gefitinib was
closed prematurely after the accrual of only 502 patients, and
all patients were taken off study drug. A similar trial with the
EGFR inhibitor erlotinib is being planned because this agent
has been shown to prolong the survival of patients with
advanced NSCLC after first-line or second-line chemothera-
py.43 A large ECOG randomized trial of chemotherapy with
paclitaxel/carboplatin plus or minus bevacizumab in patients
with advanced non-squamous cell lung cancer was reported
recently by Sandler et al.45 at the 2005 ASCO meeting. The
significant survival benefit seen in this study prompted the
development of a North American intergroup trial of chemo-
therapy plus or minus bevacizumab as adjuvant therapy after
complete resection of stages IB to IIIA NSCLC; this study is
scheduled to open shortly.
In summary, the role of adjuvant chemotherapy is now
clearly established in patients with resected NSCLC. Future
studies are needed to clarify the roles of various chemother-
apy combinations and the ideal dosing schedule and to
determine which subgroups of patients derive the most ben-
efit from treatment. However, despite significant advances in
treatment, mortality from lung cancer remains high, and
preventing this disease through global public health tobacco
reduction programs is of paramount importance.
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